VADs Set To Enter Big Leagues With St. Jude's Plan To Acquire Thoratec
This article was originally published in The Gray Sheet
St. Jude Medical says it will pay $3.4 billion to own ventricular-assist device leader Thoratec, pointing to significant synergies in the heart failure and interventional cardiology markets. The deal would thrust VADs into a diversified cardiology firm for the first time, and it includes a "go-shop" period that leaves an opening for other big device firms to enter competing bids.
You may also be interested in...
Medtronic Ups Its Heart-Failure Competitive Strength With HeartWare Buy
The deal gives Medtronic its first ventricular-assist devices and gives struggling HeartWare a needed boost.
Third Cardiovascular Giant Coming With $25 Bil. Abbott-St. Jude Deal
The previously rumored acquisition was announced on April 28, with the firms touting their extensive synergies in the cardiovascular space.
Next-Gen HeartMate Launches In St. Jude's Portfolio
Fresh-off bringing Thoratec Corp. into the fold, St. Jude Medical Inc. says its new left-ventricular-assist device unit has met a major regulatory milestone on schedule.